NEW YORK, March 10, 2015 /PRNewswire/ — Takeda Pharmaceutical Company Limited ("Takeda") today held a briefing for investors and analysts in New York, discussing the company’s gastroenterology (GI) therapeutic area.
Gastroenterology is one of Takeda’s core therapeutic areas. With a range of standard treatments and a turnover of ¥299bn (FY13), Takeda is a global leader in the field. The company presented its strategy to further expand, highlighting the global launch of Entyvio® (vedolizumab), the Japanese launch of Takecab (vonoprazan) and enhanced research and development activities.
Slides from today’s briefing and additional information about Takeda is available through its corporate website at http://www.takeda.com/investor-information/results/2014.html.
About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine.